Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection

NCT01435044 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01435044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01435044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
May 31, 2013
Enrollment
239 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic